Allergy and infectious diseases tests developer Omega Diagnostics says that second half trading was slightly better than expected.
Revenues were 28% lower at £9.76m in the year to March 2019 and there was a small second half profit. Like-for-like revenues did improve by 3%. The full year was still loss-making. Net debt was £900,000.
Food intolerance revenues grew but other parts of the business declined.
VISITECT CD4 has achieved the CE Mark and a dossier will be submitted to the expert review panel for diagnostics this month. Approval will enable NGOs to procure the VISITECT CD4 disease test.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.